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EDITORIAL REVIEW
The untoward effects of the anions of dialysis fluids
The dialysis fluids in current use contain unphysiological
amounts of the anions, acetate and n-lactate, both of which may
induce specific toxic syndromes. Elevation of blood n-lactate
above 3 m has been associated with impaired cerebral func-
tion in patients and experimental animals. Experimental studies
in animals and clinical observations of dialysis patients suggest
that an abnormally rapid rate of sodium acetate metabolism
occurring when acetate concentrations exceed the K, of acetyl
CoA synthetase of 0.7 m may lead to: I. uncoupling of
oxidative phosphorylation, lowering of the cellular phosphory-
lation potential, impairment of normal ion gradients, exacerba-
tion of glucose intolerance and increased lipid synthesis, similar
to abnormalities reported in dialysis patients; 2. precipitation
of calcium as the HP042 and inorganic pyrophosphate salts
within the mitochondrial matrix with consequent post-dialysis
hyperphosphatemia. leading to ectopic calcification of tissues,
accelerated metabolic bone disease and secondary hyperpara-
thyroidism, which require a series of marginally successful and
potentially dangerous therapies to control the hyperphosphate-
mia uncorrected by dialysis; and 3. lymphokine production of
polypeptides normally present in plasma in response to infec-
tion or trauma, produced by circulating monocytes within the
dialysis cartridge or from tissue macrophages. In patients
undergoing peritoneal dialysis it causes peritoneal fibrosis,
while in patients hemodialyzed with acetate containing fluids it
may be associated with malaise, somnolence, anorexia, loss of
bone and muscle mass and a prothrombotic state.
These findings suggest that the continued use of unphysio-
logical levels of acetate or n-lactate in dialysis fluids present a
potential but avoidable hazard. In their stead, consideration
should be given to substitution of physiological levels of the
permeant, redox-active anionic couples, i-lactate /pyruvate -,
D-/3 hydroxybutyrate/acetoacetate, and HC03/C02 used in
conjunction with precise regulation of dialysate pH so as to
fully utilize the constitutive anionic charges on serum albu-
minz. These simple changes may improve control of cellular
energy status, ion and water distribution across plasma and
mitochondrial membranes and decrease many of the most
common untoward reactions now associated with dialysis,
while at the same time improving the sense of well being in
patients.
The current dialysis fluids
Probably no group of fatally ill patients in history have been
more dependent for their continued existence upon the routine
delivery of a complex medical therapy than renal dialysis
patients. During the brief span of a quarter of a century, about
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one million people who would have died of renal failure a
generation earlier have been given seven years of added life by
dialysis alone or in combination with renal transplantation [1].
While by now this treatment is taken for granted, it is none the
less a remarkable achievement, ranking in the breadth of its
applicability to insulin treatment for diabetes. It is the purpose
of this article to suggest that the physician may improve the
care and quality of life, and better meet the needs of individual
patients by prescribing dialysis fluids which avoid the short-
comings of present dialysis fluids. The recommended proce-
dures would avoid the routine use of fluids containing un-
physiological concentrations of anions, and substitute those
naturally occurring anions which conform to the fundamental
physical chemical and metabolic organization of the cell.
The importance of fluids in dialysis
Much of the recent dialysis literature has focused on debates
about the administrative aspects of dialysis, the use of perito-
neal versus hemodialysis or ultrafiltration, and particularly the
reuse or non-reuse of dialysis membranes [2]. There has been
interest in the effect of small variations in the Na, Ca2, and
Mg2 concentration of dialysis fluids [3], but there has been no
rethinking of the fundamental principles upon which the com-
position of dialysis fluids should be based. In particular, the
results of the toxic potential of the metabolism of unphysiologi-
cal concentrations of anions used in dialysis has received only
scant attention [4] and no clinical investigation. This indiffer-
ence to the anion composition of dialysis fluids was reflected in
the recent and comprehensive National Cooperative Dialysis
Study [5], which examined the effect of high or low levels of
BUN over time [6] and the effect of the rate of hemodialysis,
but did not study the effect of dialysis fluid composition on
patient morbidity [7]. This present paper attempts to summarize
for physicians responsible for dialysis the evidence indicating
that there are simple changes in dialysis fluid composition
which may lead to improvement and propounds three major
theses: I. that much of the known morbidity associated with
current dialysis practices results from the unphysiological con-
centrations of the anions acetate and n,i-lactate used in
dialysis fluids; 2. that changes in dialysis fluid compositions to
more physiologically normal constituents and concentrations
will decrease or abolish many untoward reactions now accom-
panying dialysis; and 3. that physicians will understand both
the fundamental bases which dictate the recommended changes
and have the will to determine how physiological fluids can best
be used to the benefit of their patients.
The historical origins of current dialysis fluids
Dialysis fluids are legacies from the past created by some of
the greatest names in 19th and 20th century medicine. They
represent our practical understanding of the composition of the
body fluids, the mechanisms responsible for the creation and
587
588 Veech: Toxic anions in dialysis fluids
Table 1. Landmarks in the history of the development of parenteral
and dialysis fluids
Date Development Ref
1832 Thomas Latta gives parenteral NaCI and NaHCO3 18]
with life saving results.
1883 Sidney Ringer discovers addition of Ca2 to saline [9]
improves cardiac function.
1932 Krebs and Henseleit mimic the basic ionic [101
composition of plasma in an artificial saline by
addition of physiological amounts of
HC03/C02.
1934 Hartmann uses 36 mst n,i-lactate in Ringer's [II]
solution, thus preventing hyperchloremic
acidosis associated with infusion of large
volumes of saline.
1947 Kolif in Europe and Merrill in [iS first use [12, 131
Krebs-Henseleit in open hemodialysis baths.
1949 Mudge and Gilman propose sodium acetate as a [141
metabolizable substitute for NaHCO3.
1952 Fox used sodium acetate in parenteral electrolyte [15]
replacement fluids in surgical ratients.
1964 Scribner proposes 36 m acetate as a convenient 1161
alternative to HC03, which avoided
precipitation of Ca2 or Mg2 in open dialysis
baths.
1968 Willmore and Dudrick use 48 to 150 msi acetate 117]
to prevent acidosis in total parenteral nutrition.
1978 Scribner and others find less morbidity in [18—231
hemodialysis patients by replacing sodium
acetate with 30 to 32 msi NaHCO3 and 2 to 9
mM acetic acid.
maintenance of these compositions, and the availability of
materials to prepare and apparatus to deliver such fluids in a
clinical setting [4]. The history of the development of current
dialysis fluids is summarized in Table 1.
Table 1 shows that the development of parenteral and dialysis
fluids occurred over the past 150 years and that, when com-
pared to other major therapies used in medicine, the basic
compositions of these fluids have remained remarkably stable
over long periods. Normal saline was used first clinically in 1832
by Thomas Latta [8]. Sidney Ringer demonstrated the impor-
tance of adding Ca2 in fluid laboratory work in 1883 [9] and
Ringer's solution entered clinical use somewhat later. These
solutions have unphysiologically high Cl, and parenteral ad-
ministration leads to increased risk of hyperchioremic acidosis,
but it was not until 1932 when Krebs and Henseleit identified
the actual ionic composition of plasma water that an alternative
to C1 was considered. The composition of Krebs-Henseleit
solution was a conscious attempt to mimic the pH, buffering
capacity and inorganic ion composition of normal human plas-
ma. More importantly, it established the principle that the
optimum components and concentrations to be included in
artificial fluids are those which occur naturally in plasma.
Krebs-Henseleit improved on earlier artificial fluids because it
contained physiological concentrations of HCO and CO2
while still maintaining Ringer's vital Ca2 in solution [4].
Because of its close similarity to plasma, Krebs-Henseleit is the
ideal hemodialysis fluid. However, it never became widely used
clinically beyond the initial experiments with hemodialysis [12,
13] because of the technical difficulties with precipitation of
CaCO5. In open dialysis baths without sufficient dissolved CO2
to keep the pH at 7.4, CaCl2 and NaHCO3 combine to form
insoluble CaCO3, rendering the solution unusable. Because
solutions containing HC03 and Ca2 without adequate
amounts of CO2 were difficult to use in a clinical setting in the
1930's, alternatives were sought over the next forty years.
The substitution of sodium acetate as a metabolizable form
of sodium bicarbonate in parentera! fluids. Itwas proposed in
the late 1940's that sodium acetate was a convenient metabo-
lizable salt which could be substituted for sodium bicarbonate
[14]. Using combined mitochondrial and cytosolic processes,
the liver and skeletal muscle convert I mole of sodium acetate
into I mole of sodium bicarbonate. The introduction of 36 mri
acetate dialysis fluids in the 60's by Scribner's group [16] and
the commercial manufacture of apparatus to deliver these
fluids, coupled with the solution of the problem of vascular
access led to a rapid growth in the number of patients whose life
could be extended by chronic hemodialysis from a few hun-
dreds in the '50's to over 2,000 in the US by the end of the
decade [5]. Since the assumption of the cost of maintenance
hemodialysis by the government in 1973 [24], the numbers of
patients in the US have grown to about 75,000 in 1985 [25], of
which over 80% were being hemodialyzed with 35 to 45 mrvi
sodium acetate [3].
Themixture of sodiu,n bicarbonate and acetic acid in "bicar-
bonate" he,nodialvsis. Reports, beginning in the mid 70's, of
the untoward effects of inclusion of 35 to 45 m sodium acetate
in hemodialysis occurring since the early 1970's led to the
development of bicarbonate-based dialysis fluids, to which was
added 2 to 9 mM acetate [18—23]. Such fluids still expose blood
cells circulating through dialysis cartridges to acetate concen-
trations which are 20 to 90 times the physiologically normal
levels of 0.1 mM [261. Not surprisingly, there is still not
universal agreement that decreasing acetate in the standard
hemodialysis from 35 to 45 m to 2 to 9 m in bicarbonate
hemodialysis fluids eliminates the immediate and clinically
observable vascular and respiratory complications of acetate
hemodialysis in patients with only partially compensated
uremia [27, 28]. Recent studies on completely normal young
volunteers showed that elevation of blood acetate to only 1 mrvi
resulted in elevation of heart rate and a decrease in diastolic
blood pressure [29]. There appears to be no general realization
that the normal levels of blood metabolites such as acetate are
set at their physiological limits by the properties of the systems
responsible for their metabolism. Thus the enzyme responsible
for the initial metabolism of acetate, acetyl CoA synthetase (EC
6.2.1.1) has a K,,1 for acetate of about 0.7 mM [30]. Increasing
acetate concentrations from the normal 0.1 m to 0.7 mrt
increases the rate of acetate metabolism sevenfold to half its
maximal rate. Raising the level of acetate further, to 1 or even
45 mri, can do no more than double the rate at which acetate is
being metabolized. There is ample clinical evidence that many
individuals who chronically raise their blood acetate in liver and
blood to about 0.7 mri [31] by drinking alcohol over many years
suffer liver fibrosis and other organ damage.
The develop,nent and toxicity of D,L-lactate containing flu-
ids. As more patients came to be dialyzed, the demand for a
method which could be delivered in the home setting increased.
Thus continuous ambulatory peritoneal dialysis (CAPD) was
invented. The dialysis fluid originally prescribed was essentially
identical to the acetate-based hemodialysis fluid currently in
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use. Unfortunately, a large proportion of patients receiving
intraperitoneal acetate developed irreversible peritoneal fibro-
sis, and an alternative fluid needed to be developed. The fluid
which emerged contained reduced amounts of acetate, the
balance of which was made up with D,L-lactate. Such a formu-
lation was inspired by the lactated Ringer's solution first used
by Hartmann in 1934 [11]. He found this fluid to be life saving
in the treatment of infantile diarrhea and to possess the dual
practical advantages of not precipitating Ca2, while at the
same time preventing hyperchioremic acidosis attendant upon
the use of large quantities of normal saline or Ringer's solution.
D,L-Lactate was used because that was the only form of lactate
readily available in the 1930's. It was known at that time that
the L-form of lactic acid was the physiological form, and that
the unnatural D-form could be metabolized at only at about 20%
of the rate of the L-form, and that most of the unnatural D-form
administered to experimental animals was excreted unchanged
in the urine without being converted to glycogen 1321.
Today Ringer's Lactate and its descendants, the peritoneal
dialysis fluids, contain 36 to 45 mM D,L-lactate. The normal
level of D-lactate in the blood is below 0.02 mM [33], and the
normal blood level of L-lactate ranges from 0.5 m in fasting
man to an upper limit of about 6 m during strenuous aerobic
exercise [341. In contrast to Ringer's Lactate, the non-Cl
anionic equivalents in normal plasma are 26 to 28 mEq HC03,
14 mEq albuminate20, and only about I to 6 mEq of the major
metabolic anions L-lactate/pyruvate or o-/3 hydroxybuty-
rateJacetoacetate. Replacement of all the non-Cl anions of
plasma with D,L-lactate must inevitably result in exceeding the
normal physiological levels of both the D- and L-forms of
lactate, with differing pathological consequences depending
upon the isomeric form.
The administration of large amounts of L-lactate without a
proportionate amount of its redox partner pyruvate results in a
lowering of the cellular redox state or free [NADJ/[NADHJ
ratio, and the linked phosphorylation potential or [ATP]/
[IADP][Pi} ratio impairing many vital cellular functions,
including the distribution of inorganic ions between intracellular
and extracellular fluid [4]. Unbalanced ratios of L-lactate to
pyruvate also favor the so-called catabolic state associated with
the actions of corticosteroids and other hormones potentiating
the conversion of muscle protein into glucose [35, 36].
The toxicity of D-lactate differs from that of L-lactate in that
it is mainly observable as various forms of impaired cerebral
function. Clinical observations of patients with blind loop
syndrome and abnormal gut flora producing sufficient of the
D-isomer of lactic acid to elevate blood D-lactate to 3 mM
develop clinically demonstrable encephalopathy [37]. It had
earlier been observed in human subjects that intravenous ad-
ministration of very much lower levels of D,L-lactate solutions
can produce panic attacks [38] in a susceptible portion of the
population [39j by a variety of postulated mechanisms [40, 41].
Further increases in blood D-lactate to 20 m results in loss of
the righting reflex and subsequent frank coma in experimental
animals [421. Use of peritoneal dialysis solutions containing 40
mM D,L-lactate have been reported to result in repeated epi-
sodes of cerebral dysfunction characterized clinically by agi-
tated confusion, depression, and hyperventilation resulting in
life-threatening metabolic alkalosis [43]. In spite of 30 years of
clinical observation reporting the cerebral toxicity of the unnat-
ural D-form or the racemic D,L mixture of lactic acid, both the
US and British Pharmacopeia continue archaically to define the
only form of lactate approved for human use as the racemic
D,L-mixture. Lactated Ringer's has become the standard pen-
toneal dialysis fluid and the favored surgical resuscitation fluid
still in use today [44]. Clearly, no adequate reason for the
continued inclusion of the unnatural D-lactate in parenteral
fluids would appear to exist other than clinical habit.
At the time acetated and lactated fluids were developed, it
was not appreciated, nor was it possible to demonstrate, that
the proposed alternatives must inevitably result in profound and
undesirable metabolic consequences. This is so because the
constancy of the composition and concentrations of both the
inorganic ions and the metabolites in the plasma water are a
resultant of a dynamic interaction between the cellular meta-
bolic processes, the physical-chemical organization of the cells
and the fluids in which they are bathed. It is an inherent
property of living cells that changes in the metabolite conipo-
sit ion of the plasma or bathing fluid outside of the physiological
range must inevitably result in metabolic events which re-
establish the physiological norm. Hence dialysis fluids formu-
lated on the assumption that one metabolite is "equivalent" to
another must inevitably be inadequate. Nevertheless it is these
alternative "equivalent" fluids which are now the standard in
clinical use. A summary of the composition of current dialysis
fluids is given in Table 2.
The metabolic and medical consequences of sodium acetate in
dialysis fluids
Acetate intolerance in dialysis patients
Even though the biochemical consequences of the metabo-
lism of unphysiological levels of acetate must generally be
similar in all patients, not all patients exhibit the same clinical
signs and symptoms. Indeed a significant proportion of inves-
tigators, particularly those using low blood flow rates of less
than 300 mI/mm, 0.8 to 1.5 m2 dialysis membranes were unable
to detect acute observable clinical differences in the signs and
symptoms of patients dialyzed with 35 to 41 m acetate or
bicarbonate plus acetate [27, 28, 50]. However, a study of two
groups of patients exhibiting clinical signs of "acetate intoler-
ance" compared with a group of "acetate tolerant" patients
during routine dialysis with 35 m acetate buffers using 1.5 m2
membranes and 35 m acetate showed that the "acetate
intolerant" patients had a blood acetate at the end of dialysis of
7 to 8 mri and the "acetate tolerant", 2 to 4 mrvi [51]. This
difference in blood acetate concentration reflects a difference in
the rates at which the two groups were able to convert sodium
acetate to sodium bicarbonate.
Quite interestingly, the untoward reactions shown by the two
groups were also different. The "acetate intolerant" patients
with the 7 to 8 m blood acetate displayed the most symptoms
of vascular instability. In contrast to hypotension however,
some acute symptoms of acetate dialysis, such as hypoxia,
correlated not with the levels of blood acetate, but rather with
the rate of acetate metabolism [51, 521. While part of the
hypoxia during acetate dialysis is due to the loss of CO2 into the
CO2 free dialysis bath causing loss of respiratory drive, another
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Table 2. The compositions of current dialysis fluids
Peritoneal
Hemodialysis Lactated or
acetatedHC03/ Sodium HC03/
Normal serum CO2 acetate acetic acid Ringer's
Component [45] [12, 13] [3] [18, 21] [44]
Na 136—145 126—140 130—145 135—140 131—141.5K 3.5—5.0 0—5.4 0—4 2 (1—4
Ca0 2.1—2.6
Ca2rree 1.07 [46] 1-1.25 1.252 0.9-1.8 1,752
Mg0 0,75—1.25
Mg2rree 0.53 [471 0-1.2 0.21 04L5 0.25-O.75
Cations 145—158 133—148 133—153 139—146 132—151
mEq/liter
C1 100—106 109—121 92—Ill 105—107 96—106
HC03 26—28 24—27 0 32—33 0Pi8 1—1.45 0 0 0 0
L-lactate 0.5—5 [27] 0 0 0 0—22.5
Pyruvate 0.05—0.25 [27] 0 0 0 0
D-lactate 0.02 [26] 0 0 0 0—22.5
Acetate 0.3—0.01 [38] 0 35—40 2—9 0—45
D-/3 HBut 0.015—6 [48] 0 0 0 0
Acetoacer 0.01—1.2 [44] 0 0 0 0
A1bumin 0.5—0.8 0 0 0 0
Anions mEq/liter 130—142 133—148 132—154 139—146 132—151
Glucose 3.9—5.6 10—151 0—100 0—10 83—236
CO2 1.24—1.63 0—1.2 0 0 0
pH 7.35—7.45 7.4—8.6 6—9 [49] 7.2—7.3 6.5
Values are given in mmol/liter solution.
part is due to the fact that the metabolism of acetate results in
excessive oxygen utilization during dialysis [53]. As a result,
the "tolerant" patients with the lowest levels of blood acetate
exhibited the greatest degree of hypoxia. Work in experimental
animals provides an explangtion of this apparent paradox in that
forcing the animal to metabolize acetate at maximal rates by
elevation of blood acetate uncouples the mitochondrial process
of electron transport from oxidative phosphorylation [54] in an
attempt by the cell to maintain its essential gradient of free
[Ca2] between mitochondria and cytosol.
During acetate hemodialysis, the physiological dilemma
forced upon the patient is that if he cannot metabolize acetate at
a rate equal to that which it is being transferred his bicarbonate
falls and he becomes hypotensive. If on the other hand he
manages to metabolize the acetate at the abnormal rates forced
upon him by acetate levels above his Km of 0.7 mvs, the price is
uncoupling of mitochondria and disordering of cellular ion
gradients [54] with consequent post-dialysis hyperphosphate-
mia. However, the important fact to be derived was that both
groups were being forced unnecessarily to metabolize acetate at
grossly unphysiologlcal rates. As more physicians attempt to
shorten the time of hemodialysis to both cut costs and to
improve the quality of patient life by switching from blood flow
rates of 300 mI/mm and membranes of 0.8 to 1.5 m2 to blood
flows up to 1000 ml/min with membranes of 5 m2 surface area
[551, the untoward effects resulting from the demand of an
unphysiological rate of acetate metabolism are likely to become
even more apparent.
The effects of sodium acetate upon blood interleukin-1 and
other "middle molecules," and the symptoms associated
with dialysis
Neurological dysfunction is part of the uremic syndrome [56],
and can be dramatically reversed by dialysis [57]. However,
rapid electrolyte and water shifts during dialysis itself can lead
to another form of neurological dysfunction termed "disequili-
brium syndrome" [58]. Interviews with dialysis patients under-
going chronic hemodialysis suggest that there is yet a third more
subtle form of neurological dysfunction associated with dialy-
sis. Patients speak of feeling "washed out" or "having been
through a war" and show somnolence, lethargy, loss of energy,
anorexia and weakness without muscle aches reminiscent of the
"malaise" accompanying a viral illness. These feelings often
last for 12 to 24 hours following each dialysis session. The cause
of these symptoms, their definition and their quantitation has,
however, been difficult 1591 beyond the recognition that they
represent some form of central nervous system dysfunction of
unknown etiology similar to that seen during infection, and
there is now a biochemical hypothesis to explain the clinical
observations.
The old clinical hypothesis that uremic toxins, dubbed "mid-
dle molecules" [60, 61] of a few thousand molecular weight,
accumulate in the blood of uremics and account for some of the
uremic symptoms has been given new credence. Recently it has
been reported that the activity of the potent lymphokine
interleukin- 1, which is normally released during the acute phase
of injury or infection, is elevated eightfold in uremics at the end
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of the interdialytic period increasing to 12-fold elevation at the
end of standard 40 mi sodium acetate hemodialysis [621.
Contrary to the expectation that uremic toxins would be re-
moved from the blood by increasing the pore size of dialysis
membranes to allow passage of molecules of several thousand
molecular weight, the interleukin-l data clearly show that the
process of acetate dialysis increases the activity of this peptide
in a manner which roughly parallels the "malaise syndrome"
reported by a number of hemodialysis patients.
Native interteukin-1 a and /3 [63] are now known to be
peptides of 17,000 molecular weight normally produced by cells
of the monocytic series such as monocytes, macrophages,
Kupifer cells and other cells [64, 65] in response to infection or
trauma [66]. Interleukin-l has had a variety of names such as
endogenous pyrogen, lymphocyte activating factor [67] and
catabolin [68], which emphasize the protean nature of its
actions [69] some of the more important of which are in this
context:
1. interaction with brain to produce fever [70], anorexia, som-
nolence and astrocyte proliferation [71]
2. stimulation of fibroblast proliferation, secretion of collogen
and production of prostaglandin E2 [72]
3. activation of proteolysis in muscle [68]
4. activation of osteoclasts to produce bone resorption [70]
5. production of a procoagulatant state in vascular endothelial
cells [73] and proliferation of vascular smooth muscle cells
[64].
In its actions, interleukin-l shares many of it effects, such as
fibroblast stimulation and bone and muscle wasting, with other
small molecular weight peptides produced by cells of the
monocytic series, such as tumor necrosis factor a and /3, [74]
and the oncogene product platelet-derived growth factor [753.
To date the role of these other peptides in uremia and dialysis
has not been studied; however, it seems almost certain that the
factors leading to release of interleukin-1 from activated
monocytes might also lead to the release of these other
peptides.
The findings that plasma interleukin-l activity is further
increased from 8 to 12 times normal by standard acetate
hemodialysis [62], and that dialysis of human blood in vitro
against a dialysing fluid containing 10 m sodium acetate
caused an increase in blood interleukin-l activity [76] strongly
suggest that exposure of circulating blood containing mono-
cytes to dialysis fluids containing unphysiological levels of
acetate may contribute to the elevation of this powerful lym-
phokine in patients undergoing dialysis. While the acute rise in
plasma interleukin levels during hemodialysis may also result
from surface activation of the complement cascade by the
dialyzer membrane [77], such a mechanism seems unlikely to be
the major factor accounting for elevation of this material in the
intradialytic period, Since the half-life of interleukin-1 is a
matter of hours, the persistence of elevated interleukin-1 sug-
gests a chronic stimulation of interleukin producing cells, as in
alcoholic hepatitis where a 9.8-fold elevation of plasma
interleukin-l [78] follows chronic exposure to blood acetate of
about 1 mM.
The relationship between inclusion of 36 m acetate in
peritoneal dialysis fluids and the loss of ultrafiltration capacity
and induction of irreversible peritoneal dialysis fibrosis [791 is
now understandable based on the known ability of interleukin-1
to stimulate fibroblast proliferation and collagen synthesis. The
minimum levels of acetate required to stimulate interleukin-1
level from cells of the monocytic series in vivo are not known.
However, alcoholics who metabolize ethanol to acetate within
the liver, develop levels of blood acetate of only 1.8 m in
hepatic vein and 0.9 mivi in systemic veins [31, 80], and about
30% of these alcoholic patients go on to develop the classic
central hyaline sclerosis with fibrosis and Mallory hyaline
bodies clinically recognizable as alcoholic cirrhosis. A small
proportion of diabetic patients also develop a cirrhosis patho-
logically indistinguishable from alcoholic cirrhosis [81]. Diabet-
ics, like alcoholics have been shown to have an elevated mean
fasting venous acetate of 0.29 mM, with a maximum reported
acetate of 0.8 mrvi [823.
The clinical association between acetate peritoneal dialysis
fluids and peritoneal fibrosis [83] caused the removal of these
fluids from sale. No technological limitation, other than habit,
requires that acetate continue as a component in either acetate
dialysis fluids or in so-called bicarbonate dialysis fluids.
Acetate was proposed as a metabolizable alternative to
bicarbonate [14—16]. To accomplish this transformation of so-
dium acetate into sodium bicarbonate within the body during
normal acetate hemodialysis, acetate must be metabolized at
the maximal rate of 300 mmol/hr [31, 84]. The first step in the
metabolism of acetate is its activation by acetyl CoA synthetase
(EC 6.2.1.1) located on the outer mitochondrial membrane and
within the mitochondrial matrix [85, 86] in the reaction:
Acetate + ATP4 + CoASH — Acetyl CoA
+ AMP2 + PPi3 (eq 1)
The acetyl CoA formed by the activation of acetate is subse-
quently converted to CO2 and 1120 within the mitochondrial
matrix by the action of the Krebs tricarboxcylic acid cycle [87].
The net stoichiometry of the complete conversion of sodium
acetate to sodium bicarbonate is:
NaAcetate + 4H20 + 3NAD + FAD + ADP3 + Pi2
NaHCO3 + CO2 + 3NADH + 3H + FADH2
+ AMP2 + PPi3 (eq 2)
As equation 2 shows, the complete metabolism of 1 mole of
sodium acetate does indeed lead to the creation of I mole of
sodium bicarbonate, but as equation 2 also suggests, that
process of metabolic conversion at the maximum rate possible
also leads to: 1) a build up of inorganic pyrophosphate (PPi)
within the cell, and 2) a diversion of the cell's metabolic energy
from maintaining the central energy parameter, the phosphor-
ylation potential. In Table 3 a summary of the far-reaching
disorder induced in multiple biochemical pathways by metabo-
lizing 10 to 20 m sodium acetate in the liver of 200 to 250 male
Wistar rats is compared to some of the common untoward
complications accompanying standard 35 to 41 mrvi hemodialy-
sis in patients.
Clearly, there are many undesirable metabolic effects result-
ing from the conversion of sodium acetate to sodium bicarbon-
ate such as: 1) the abnormalities induced in glucose and lipid
homeostasis; 2) the remarkable precipitation of three times the
circulating blood calcium as pyrophosphate within the mito-
chondria and the resultant postdialysis hyperphosphatemia,
Metabolic effect
1. Glucose: increased 1.6- to 1.7-fold;
glycolytic intermediates
increased 2- to 3-fold
2. Lipids: increased malonyl CoA
1.4- to 2.2-fold, doubling rate of
fatty acid synthesis
3. Adenosine: AMP increase favors
adenosine release into
circulation
4. Inorganic phosphate: increased
from 1.4- to 1.9-fold inside cells
being taken from bone
5. PPi, Ca2 and Mg2: increase up
to 100, 2.5, & 1.2 times,
respectively, removing Ca2 and
Pi from bone during acetate
metabolism to return to blood
after acetate goes
6. CaPPi and MgPP1: forms in
mitochondria during acetate
metabolism
7. Activation of acetate at
concentrations above km of 0.7
m does not increase
conversion to HC03
appreciably
8. Uncoupling oxidative
phosphorylation: results from
acetate metabolism
9. [EATP]/[ADP][Pi] Decrease:
impairment of the extent and
direction of many vital metabolic
reactions.
Ref Clinical reports
[54] Glucose intolerance of uremia exacerbated
and management of diabetes complicated
Hypertriglyceridemia with worsening of
accelerated vascular disease in this
group
Hypotension, vascular instability during
hemodialysis
Hyperphosphatemia of uremia is
uncorrected by dialysis due to Pi
accumulation inside cell
Metabolic bone disease, and
hyperparathyroidism follow while
aluminum intoxication triad of dementia,
anemia and osteomalacia result from
[103] Al(OH)3 given to lower Pi
[541 Ectopic calcification of vasculature and
soft tissue worsened by high free Ca2
in dialysate when Pi is elevated
[54] Chronic metabolic acidosis acetate
conversion to HCO is at limiting rate
in man, but leaves patients acidotic, thus
adding to bone disease
[541 Hypoxia and increased circulatory demand
due to increased 02 needs
Abnormal electrolyte and H20 distribution
between extra- and intracellular space
[88]
[89]
[90]
[18]
[19]
[211
[94]
[95]
[96]
[971
199]
[101]
[102]
[104]
[1051
[106]
[107]
[108]
[1091
[SI]
[52]
[53]
secondary hyperparathyroidism, metabolic bone disease and
ectopic calcification; and 3) the uncoupling of oxidative phos-
phorylation with the attendant drop in the critical cellular
[ATPI/[ADP]LIPiJ ratio. These untoward effects make the
casual use of sodium acetate as a convenient source of bicar-
bonate untenable. Acetate, instead of restoring the electrolyte
and fluid balance during dialysis, adds to the disorder.
Fundamental principles determining the composition of more
physiological dialysis fluids
It is a fundamental property of living systems that the
chemical composition of both the intra- and extracellular fluids
is closely regulated [113]. The composition of the plasma is a
creation of the cells which it bathes [4]. If cells or organs are
perfused with fluids which differ from the composition of
normal plasma, they immediately begin to adjust the composi-
tion of the bathing media toward the normal physiological state.
The composition of the major ionic components of plasma
represents the aggregate thermodynamic limits of only a very
few, fundamentally linked systems [4, 54, 118]. The major
metabolic factors controlling the electrolyte and water compo-
sition of plasma are: 1) the concentration and charge of
impermeant Donnan active ions [114, 1151; 2) the pH deter-
mined by the physiologically normal [HC03]/[C02J buffer
couple [1161; 3) the redox states of the [NADJ/[NADH1
couples determined by permeant monoanionic metabolite pairs,
L-lactate !pyruvate - or D-/3 hydroxybutyrate 7acetoacetate -,
[1171; and 4) the cellular phosphorylation state or [IATP]/
[ADP][Pi] ratio linked to the cellular redox states [117] and
ion distributions [4, 54, 118].
The major practical problem in creating an artificial fluid
which mimics the composition of plasma has been the question
of how to fill the anion gap, or the difference between the 136 to
145 mEq of Na plus the 6.5 to 8 mEq of other cations in plasma
and the 100 to 106 mEq/liter of C1 (Table 2). It is now
technically practical to use fluids that approximate the compo-
sition of normal human plasma, where the missing anions are
supplied by: 26 to 29 mEq HC03/1.6 m C02, 14 mEq of
albuminate20, 2 to 6 mEq of L-lactate/pyruvate or D-/3
hydroxybutyrate/acetoacetate, and about 1.8 mEq of Pi'
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Table 3. Summary of the consequences of metabolism of 10—20 mM sodium acetate in rat liver with reported untoward effects of acetate
hemodialysis in patients
Ref
[54]
[91]
[92]
1931
[4]
[54]
[4]
1541
[98]
[1001
[4]
[110]
[111]
[112]
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and still keep the physiological concentrations of free [Ca2]
and [Mg2] in solution.
Suggested components of physiological dialysis fluids
If the present dialysis fluids are less than optimal, then
improved results could be expected by very simple changes in
anionic composition. The new fluids should be prescribed so
that:
1. The levels of acetate in all fluids should not exceed the
normal physiological limit of 0.1 mi.
2. In bicarbonate dialysis, either CO2 should be added as the
acid to replace acetic acid, or alternatively, the permeant
redox active monoanion pairs L-lactate/pyruvate at ratios
of about 7/1 or D-/3 hydroxybutyrate/acetoacetate at ratios
of about 2/1 in their acid forms should replace the acetic acid
added to bicarbonate at acid levels not exceeding the phys-
iological limits of 5 to 6 mM.
3. In hemodialysis, advantage should be taken of the variable
anionic charges present on serum albumin to reduce the
levels of metabolic anions required in fluids.
4. The use of D,L-lactate should be eliminated and replaced
with mixtures of the above listed, physiologically-normal
redox active couples so as to prevent cerebral dysfunction
and to insure normality of the cellular [ATP][ADP][Pi]
ratio and with it normal ion distributions.
5. Prescribed dialysis fluids should be tailored to the needs of
the individual patient.
At first glance, it may appear startling to suggest that physi-
cians, who have been taught to fear "lactic acidosis" and to
treat "ketosis", should now consider prescribing fluids contain-
ing physiological ratios of L-lactate/pyruvate or D-f3 hydroxy-
butyrate/acetoacetate to patients. There is, however, no
basis for this reaction since these couples are unique among all
metabolic anions in being: 1) the predominant anionic metabolic
fuel, 2) permeant to plasma membranes of most cells, and 3)
capable of regulating the intracellular NAD redox states and
with that the phosphorylation potential. When given within the
physiological limits of concentration, no abnormal reactions
can be anticipated.
Serum albumin, the unused anion of hemodialysis
In concentrating upon anions such as acetate and D,L-lactate,
a naturally occurring anion has been ignored in dialysis as a
filler of the anion gap. This unused anion is the 0.5 to 0.8 mM
albumin20 present in normal blood plasma. After Cl and
HC03, the natural anionic charges on albuminz_ are the most
abundant in plasma, and are ideal during hemodialysis to
replace the unphysiological levels of anions such as acetate,
thus avoiding their toxicity by using material supplied by the
patient himself. By allowing dialysis fluid pH to vary over a
considerable range from about 6 to 9 [53] with the bulk of fluids
being pH 6.5, a major source of natural anions in hemodialysis
has remained unused. The pH of the dialysis solution deter-
mines whether the charge on the albuminz_ in the patient's
blood approaches 0 at pH 6 or is greater than 30 Eq/mol at pH
9. The relationship between the charge, Z, on serum albumin
and the pH of the solution in which it exists is a fundamental
one. By acting as an impermeant Donnan active ion [114], in
combination with the concentration of ions in the dialysis fluid
Table 4. Estimated electrolyte composition expected in plasma
returning to the patient after dialysis
Normal
serum
[49]
Initial
dialysate
HCO3/C02
Return
plasma
Final
dialysate
HCO3/C02
Return
plasma
Cations mMNa 136—145 150 144 141 136.5K 3.5—5.0 2.0 1.9 2.6 2.5
[Ca2] [1.07] 1.1 1.08 1.1 1.1
[Mg2'i [0.53] 0.5 0.49 0.5 0.5
Cations 142.7—153.2 155.2 149 146.8 142.2
inEqiliter
Anions mMCl 100—106 128 116.6 102 92.1
HC03 26—28 27.5 24.8 44.8 40.5
Acetate <0.1 0 0 0 0
A1bz 16—19 0 8.6 0 9.6
mEqiliter
Z Anions 142—152 155.2 149 146.8 142.2
CO2 1.0—1.5 3.12 2.91 1.78 1.66
pH 7.34—7.45 7.0 7.0 7.5 7.5
Glucose 3.9—5.6 5 4.7 5 4.7
Na/Cl 1.28—1.45 1.17 1.23 1.38 1.48
Values are given as mmol/liter solution. The assumed albumin
concentration is 3 g/dl or 0.43 mi with charge on albumin as defined by
pH [121]. F I denote the free concentrations.
it acts to determine [4]: 1) the concentration of permeant anions
transferred to the patient, and 2) the concentration of cations
returning to the patient.
The Tanford Relationship: Describing the relationship be-
tween pH and the anionic charge Z on serum albuminz_.
Serum albumin, the most common serum protein of molecular
weight 69,000, normally is present in amounts ranging from 0.5
to 0.8 mmol!liter serum. It carries about 20 anionic charges per
mole at pH 7.4, accounting for 10 to 16 mEq/liter of the normal
plasma anions.
The precise relationship relating pH to the charge per mole on
serum albumin was first described by Charles Tanford [1191,
and within the pH range of dialysis fluids is a straight line of the
form y = mx + b
The Tanford relationship between pH and charge JZJ on
albumin [119]
IZ = —8.7 x pH + 43
where: Zi = absolute value of charge on albumin at 38°C and
0.15 M NaCl, —8.7 = slope of line relating charge on albumin on
the y axis versus pH on x axis, and 43 = y intercept of that line.
The Tanford Relationship states that at pH 5, serum albumin
would have no net charge; at pH 6.5, the pH of most sodium
acetate dialysis fluids, it would have 13 anionic charges/mole, at
pH 7.4, 21 anionic charges/mole and at pH 8.8, 33 anionic
charges. The electrolyte composition of the fluid returning to
the patient can therefore be varied simply by varying the charge
placed on the patient's own albumin [4]. Using CO2 as the acid
to control pH does not require the metabolism of the acid added
to control pH and prevent Ca2 precipitation, thus avoiding
most of the complications attendant on the use of other acids
such as acetate or D,L-lactate.
Example of the effects of changing charge upon albumin of
ionic composition of fluid returning to patient. The effect of
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varying the charge upon albuminz_ is given in Table 4 and
shows how the resultant Donnan equilibrium 1114] effects the
concentration of ions in the hemodialysis fluid and plasma
returning to the patient from the dialysis cartridge.
It is immediately obvious that the magnitude of the charge on
the albuminz_ in the plasma changes the electrolyte composi-
tion of the fluid returning to the patient, even in this hypothet-
ical case where pH was changed only from 7.0 to 7.5 and the
albumin levels were only half normal values of 0.4 m. The
effect of the fixed anionic charges in plasma is to reduce the
concentrations of anions in the dialysis fluid which actually
return to the patient from the dialysis bath. Additionally, the
ratio of Na/Cl in the plasma increases toward the normal in
the plasma returning to the patient in comparison with that
present in the dialysis fluids, and this effect increases with the
increasing charge on the albumin. In short, albuminz_ is acting
like an impermeant anion, resulting in a classic Donnan distri-
bution of all permeant charged species, and can be a useful tool
in hemodialysis [4j, which is very much decreased at pH's of
6.5 characteristic of most current acetate dialysis fluids.
The control of pH in dialysis fluids
With the reappearance of interest in the use of HC03 instead
of acetate in both peritoneal and hemodialysis, some acid had to
be added to the dialysis fluids to prevent precipitation of the
added Ca2t Since the pH of pure bicarbonate is about 8.6 and
the PKa2 of carbonic acid is about 9.8, at pH of 8.6, about 5% of
FlCO3 exists as C032. Because C032 combines with Ca2 to
form insoluble CaCO3, 2 to 9 mivi acetic acid was added to
prevent this problem [18, 21]. This inappropriate use of acetic
acid is both unphysiological and unnecessary.
The chosen acid to regulate pH of a bicarbonate buffer is
carbonic acid, the hydrated form of CO2 gas [116]. The original
hemodialysis fluids [12, 13] used CO2 gas as the acid in dialysis
baths. Since addition of acetic acid to bicarbonate dialysis fluid
forms CO2 in situ, but leaves abnormal levels of acetate to be
disposed of metabolically, it seems far better to simply add the
CO2 to the fluids themselves. The use of CO2 has therefore been
proven to be safe by previous clinical experience. The technol-
ogy required to add CO2 to large amounts of water has existed
since the days of the first soda fountain 1121]. The determina-
tion of precisely the proper amount of CO2 required is also well
known.
The partial pressure of CO2 in arterial blood of normal
humans is 35 to 45 mm Hg [49] and, more relevant to the
situation in hemodialysis, 50 to 55 mm Hg in venous blood
returning from the cells and in the intracellular water [116, 120].
Acetate-free hemodialysis fluids can be made simply by equil-
ibrating gaseous CO2 with HC03 solutions to achieve the pH
desired in the following manner.
partial pressure CO, cCO2[C02] in mmol/liter = - x x 1000
atmospheric pressure Vco,
where: aCO2 = 0.553 in serum at 37°C [121], Vco, (mole
volume) = 22.26 liter/mol at 0°C, and 25.6 at 38°C.
At 50 mm Hg, the partial pressure of CO2 of venous blood,
the normal CO2 concentration is therefore about 1.41 mM, or
about equivalent to a gas containing 7% CO2. Since the con-
centration of bicarbonate in venous plasma is 26 to 28
mmollliter plasma, from the Henderson-Hasselbalch equation
[114]:
pH = 6.1 + log{[HC03]/[C02]
pH = 6.1 + log{26 mM/l.41 mM}
pH 7.37
While concentrations of CO2 up to 21.6 m, or 15 times
physiological levels, can be obtained by this means, in practice
levels very close to physiological concentrations would be
required in most hemodialysis situations. This has many advan-
tages over the use of acetic acid which must be added to
bicarbonate at levels which are 20 to 90 times the physiological
level. Unlike the use of other acids such as acetic acid, the
advantages to be gained by the use of CO2 may be summarized
as follows:
1. CO2 is the normal physiological acid used to regulate PH;
2. Carbonic acid is a stronger acid than acetic and can be used
at physiological levels to attain a precise pH in bicarbonate
hemodialysis fluids;
3. CO2, unlike acetic acid, does not require metabolic pro-
cesses for its removal, but is removed on one passage
through the lungs;
4. CO2 will eliminate the hypopnea and consequent anoxia
[122] resulting from loss of respiratory stimulation during
acetate dialysis.
Use of Donnan distributions, CO2 and C1 as possible
approach to chronic hyperphosphatemia and acidosis in
hemodialysis
Use of the type of fluid described offers potential to solve
some of the accepted deficiencies of hemodialysis. The present
hemodialysis procedures leave patients with at least two major
metabolic problems, chronic metabolic acidosis and chronic
hyperphosphatemia. Patients undergoing hemodialysis with 35
to 41 m sodium acetate end the interdialytic period with
venous HC03 of about 18 mr.i [109], as do those being dialyzed
with 32 mri HC03 plus 4 m acetate [90]. Using the Donnan
equations for distribution of ions [4, 112], it may be calculated
that the patients dialyzed against 32 m HC03 and 4 mM
acetic acid at pH 7.25 [90] received only 28.3 m HC03 and
3.6 mrs acetate in the blood returning to the patient. Since
normal serum bicarbonate is 26 to 28 mrs, it is not surprising
that the bicarbonate reserve was depleted in a two day period
between dialyses. It would appear from these data that the
patients accumulated about 8 mmol/liter body water/day of
metabolic acids from dietary and metabolic sources during the
interdialysis period. To keep such patients in a normal bicar-
bonate range over a two day period, one would have to make
bicarbonate about 36 m in body fluids at the end of a dialysis
treatment.
Infused bicarbonate, however, with its accompanying cation,
approximately equilibrates throughout total body water [1231.
Infusion of bicarbonate must inevitably be accompanied by
cations, including Na and Ca2 [4], and this can result in
sequestration of intracellular Ca2 and Pi [54]. This adds to the
second persistent problem of present fluids, chronic hyper-
phosphatemia which results from the sequestration of PPi and
Pi within the intracellular space [102] where it is inaccessible to
removal by dialysis. The intracellular phosphates are subse-
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quently released into blood in the six hours following hemodi-
alysis [95]. While use of acetate free dialysis fluids will help in
combatting this problem, more aggressive measures can be
taken to literally wash the Pi out of the inside of cells during
dialysis.
In addition to keeping the phosphoryltion potential in the
high normal range by avoidance of addition of substrates, such
as acetate or lactate to dialysis fluids which both lower the
phosphorylation potential and also increase the intracellular
phosphorylated intermediates [4, 98], one may take advantage
of the special properties of C1 as the only common anion which
is permeant to plasma membrane in a voltage-dependent man-
ner unaccompanied by cations [4]. If initial dialysis fluids which
are high in Cl are used in solutions which have normal
contents of HC03 and C02, it seems likely that intracellular Pi
could be reduced to a minimum. This high C1 dialysis to
remove increased intracellular Pi could then be followed in a
linear gradient with HC03 rich dialysis fluids to give the
patient sufficient alkali reserve to go through the intrdialytic
period oscillating around the neutral point without being chron-
ically acidotic, with all of the complications for metabolic bone
disease which accompanies metabolic acidosis [124]. Attaching
the two fluid concentrates together in a manner to form a linear
gradient between the two delivered solutions is a proposed
approach to the problem of hyperphosphatemia and chronic
acidosis. It can be easily accomplished with only minor modi-
fications of existing equipment. The provision of such minor
modifications in equipment should allow physicians to test the
premise that the many variations possible using more physio-
logically compatible components in dialysis fluid can offer
better care for their individual patients, while at the same time
removing some of the chronic problems experienced by dialysis
patients since the practice of dialysis began.
The proposed alternatives really stem from application of
those first principles which form the scientific basis of our
understanding of fluid and electrolyte and acid-base balance [4].
Without detailing the intimate and elegant biochemical mecha-
nisms responsible, the major practical guide to be followed, first
clearly formulated by Claude Bernard in 1878 [1131, is that a
fundamental property of living organisms is the maintenance of
the constancy of the internal environment. It follows that the
major empirical guide to improve dialysis fluid compositions is
the composition of normal human plasma, as Krebs understood
in a practical application 50 years ago when he made Krebs-
Henseleit [10]. It is the restoration of that predetermined
constant internal environment which is the primary aim of
dialysis, and to best achieve that aim with the least metabolic
disorder, dialysis fluid compositions should logically follow
plasma compositions as closely as possible.
RICHARD L. VEECH
Easton, Maryland, USA
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